These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16013931)

  • 21. Clinical outcome to clozapine treatment in chronic psychiatric inpatients.
    Advokat CD; Bertman LJ; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Jan; 23(1):1-14. PubMed ID: 10368852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insight into illness and attitudes toward medications among inpatients with schizophrenia.
    Sajatovic M; Rosch DS; Sivec HJ; Sultana D; Smith DA; Alamir S; Buckley P; Bingham CR
    Psychiatr Serv; 2002 Oct; 53(10):1319-21. PubMed ID: 12364685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
    Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
    J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
    Jalenques I; Ortega V; Legrand G; Auclair C
    Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone augmentation of neuroleptics in schizophrenia.
    Sernyak MJ; Glazer WM; Heninger GR; Charney DS; Woods SW; Petrakis IL; Krystal JH; Price LH
    J Clin Psychopharmacol; 1998 Jun; 18(3):248-51. PubMed ID: 9617985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes.
    Chanpattana W; Kramer BA
    Schizophr Res; 2003 Sep; 63(1-2):189-93. PubMed ID: 12892873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Schizophrenia diagnostic announcement in a French psychiatric unit].
    Rocamora JF; Benadhira R; Saba G; Stamatadis L; Kalalaou K; Dumortier G; Plaze M; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2005; 31(4 Pt 1):449-55. PubMed ID: 16389712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia.
    Bressan RA; Costa DC; Jones HM; Ell PJ; Pilowsky LS
    Schizophr Res; 2002 Jul; 56(1-2):31-6. PubMed ID: 12084417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
    Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
    Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Factors related to treatment adherence in schizophrenic patients].
    García Cabeza I; Sánchez Díaz EI; Sanz Amador M; Gutiérrez Rodríguez M; González de Chávez M
    Actas Esp Psiquiatr; 1999; 27(4):211-6. PubMed ID: 10469940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.